Eli Lilly and Company (NYSE:LLY) Shares Acquired by Fairfield Financial Advisors LTD

Fairfield Financial Advisors LTD lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,668 shares of the company’s stock after buying an additional 29 shares during the period. Eli Lilly and Company makes up about 4.0% of Fairfield Financial Advisors LTD’s investment portfolio, making the stock its 10th largest holding. Fairfield Financial Advisors LTD’s holdings in Eli Lilly and Company were worth $11,324,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Naviter Wealth LLC boosted its position in shares of Eli Lilly and Company by 82.4% during the fourth quarter. Naviter Wealth LLC now owns 10,019 shares of the company’s stock worth $7,734,000 after buying an additional 4,525 shares during the period. Rialto Wealth Management LLC acquired a new stake in Eli Lilly and Company in the fourth quarter worth approximately $121,000. Hamilton Capital Partners LLC acquired a new stake in Eli Lilly and Company in the fourth quarter worth approximately $5,177,000. Lifeworks Advisors LLC lifted its position in Eli Lilly and Company by 13.6% in the fourth quarter. Lifeworks Advisors LLC now owns 8,154 shares of the company’s stock worth $6,295,000 after purchasing an additional 975 shares during the period. Finally, Intellectus Partners LLC lifted its position in Eli Lilly and Company by 153.4% in the fourth quarter. Intellectus Partners LLC now owns 1,077 shares of the company’s stock worth $832,000 after purchasing an additional 652 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LLY has been the subject of a number of research analyst reports. Citigroup cut their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday. Wolfe Research began coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target on the stock. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Finally, Truist Financial upped their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,007.50.

Eli Lilly and Company Trading Down 4.8 %

Eli Lilly and Company stock opened at $868.59 on Friday. The company’s fifty day simple moving average is $826.63 and its 200-day simple moving average is $848.68. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The stock has a market cap of $823.57 billion, a P/E ratio of 74.17, a P/E/G ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is currently 51.24%.

Eli Lilly and Company declared that its board has approved a stock repurchase plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.